Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Further clinical data reported on cancer vaccine MGN-1601 at ESMO

Oct. 1, 2012

Northwest Biotherapeutics prepares for phase I/II DCVax-Direct study

Sep. 26, 2012

Ablynx and Merck Serono advance ALX-0751 into preclinical development

Sep. 26, 2012

Biovest provides update on planned MAA for NHL vaccine candidate

Sep. 21, 2012

Patrys cleared to commence phase I/IIa PAT-SM6 study

Sep. 21, 2012

Gamida Cell completes enrollment in phase I/II NiCord study

Sep. 20, 2012

Bionomics acquires Biogen's oncology spin-off

Sep. 18, 2012

Researchers from Peregrine present topline results from a phase II study in NSCLC

Sep. 12, 2012

Actinium to begin screening patients for second cohort of phase I/II trial in AML

Sep. 10, 2012

Symphogen licenses Sym-004 to Merck KGaA

Sep. 10, 2012

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...